931305-29-2
Chemical Structure
Bt354
- CAS No.: 931305-29-2
- Formula:C21H21N3O3S
- Molecular Weight:395.48
IUPAC Name: 4-methyl-3-((4-methylphenyl)sulfonamido)-N-(pyridin-3-ylmethyl)benzamide
InChIKey: YEXAAWTTYIXUIP-UHFFFAOYSA-N
SMILES: O=C(NCC=1C=NC=CC1)C2=CC=C(C(=C2)NS(=O)(=O)C3=CC=C(C=C3)C)C
Biological Activity: Bt354 is an orally active STAT3 inhibitor with IC50 values of 4.6 μM (DU145), 6.5 μM (MDA-MB-435) and 7.2 μM (MDA-MB-231), respectively. Bt354 induces cell cycle arrest and apoptosis, and downregulates epithelial-mesenchymal transition-related genes. Bt354 exhibits anti-angiogenic and anti-inflammatory activities, attenuates the polarization of M1 microglia and A1 astrocytes, suppresses inflammasome-related signaling pathways, and alleviates mechanical hyperalgesia and thermal hyperalgesia. Bt354 can be used in research related to glioblastoma multiforme, triple-negative breast cancer, prostate cancer and neuropathic pain[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bt354 | Bt354 is an orally active STAT3 inhibitor with IC50 values of 4.6 μM (DU145), 6.5 μM (MDA-MB-435) and 7.2 μM (MDA-MB-231), respectively. Bt354 induces cell cycle arrest and apoptosis, and downregulates epithelial-mesenchymal transition-related genes. Bt354 exhibits anti-angiogenic and anti-inflammatory activities, attenuates the polarization of M1 microglia and A1 astrocytes, suppresses inflammasome-related signaling pathways, and alleviates mechanical hyperalgesia and thermal hyperalgesia. Bt354 can be used in research related to glioblastoma multiforme, triple-negative breast cancer, prostate cancer and neuropathic pain. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Chiang YC, et al. STAT3 phosphorylation inhibitor Bt354 exhibits anti-neoplastic activity in glioblastoma multiforme cells. Environ Toxicol. 2024;39(6):3292-3303. [Content Brief]
- [2]. Cheng HJ, et al. Intrathecal STAT3 inhibitor Bt354 ameliorates chronic constriction injury-induced nociceptive sensitization by modulating neuroinflammation. Neurotherapeutics. 2025;22(6):e00763. [Content Brief]
- [3]. Chen Y, et al. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer. J Drug Target. 2018;26(10):920-930. [Content Brief]
Keywords
